Eterna Therapeutics
Yahoo Finance • 11 days ago
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation a... Full story
Yahoo Finance • 13 days ago
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjee... Full story
Yahoo Finance • 25 days ago
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented... Full story
Yahoo Finance • last month
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featur... Full story
Yahoo Finance • 3 months ago
Ernexa regains Nasdaq compliance, continues trading on exchange
CAMBRIDGE, Mass. - Ernexa Therapeutics (NASDAQ:ERNA) has regained compliance with Nasdaq’s minimum bid price requirement for continued listing, the company announced Wednesday. The biotech firm, currently valued at $14.1 million, has seen... Full story
Yahoo Finance • 3 months ago
Ernexa Therapeutics changes independent auditor to Haskell & White
Ernexa Therapeutics Inc. (NASDAQ:ERNA), a small-cap biotech company currently valued at $13.54 million and showing signs of financial strain according to InvestingPro data, announced a change in its independent registered public accounting... Full story
Yahoo Finance • 4 months ago
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Adv... Full story
Yahoo Finance • 4 months ago
Ernexa Therapeutics registers 57M shares for resale
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) is registering 57.05M shares of common stock for resale by selling stockholders. * Includes 47.7M outstanding shares and 9.3M shares issuable upon exercise of p... Full story
Yahoo Finance • 4 months ago
Ernexa Therapeutics announces 1-for-15 reverse stock split
Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common St... Full story
Yahoo Finance • 4 months ago
Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) trades -19% as the Co. announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share, at a ratio of 1-for-15 [h... Full story
Yahoo Finance • 4 months ago
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued... Full story
Yahoo Finance • 5 months ago
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at t... Full story
Yahoo Finance • 5 months ago
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly... Full story
Yahoo Finance • 6 months ago
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at... Full story
Yahoo Finance • 7 months ago
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today announced a successful inaugural meeti... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transf... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel engineered iPS cell line to be evaluated by Lineage for potential development of ce... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with trans... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transf... Full story
Yahoo Finance • 2 years ago
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease Presentations to include additional advances in nucleic-acid delivery and targeted... Full story
